SCHEMBL742291

SCHEMBL742291

c1coc(Cc2ccc3ccccc3n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.46
KDM4E B2RXH2 4/20 0.44
MAPT P10636 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 2/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
MCL1 Q07820 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYSLTR2 Q9NS75 1/20 0.44
CYSLTR1 Q9Y271 1/20 0.44
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.41
HSD17B10 Q99714 3/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580145 0.81 ALDH1A1 (0.38) PDE10AKDM4EMAPTKMT2AMEN1
SCHEMBL30879956 0.79 CYSLTR1 (0.57) PDE10AMAPTCYSLTR2CYSLTR1LMNA
SCHEMBL3267444 0.79 CYSLTR1 (0.57) PDE10AMAPTCYSLTR2CYSLTR1LMNA
SCHEMBL4938792 0.77 CYSLTR1 (0.55) PDE10AMAPTCYSLTR2CYSLTR1LMNA
SCHEMBL28127871 0.73 MAPT (0.39) PDE10AKDM4EMAPTKMT2ANPC1
SCHEMBL16248323 0.72 SMN1; SMN2 (0.54) KDM4EMAPTKMT2ANPC1RAB9A
SCHEMBL10548410 0.72 CYSLTR1 (0.59) PDE10ACYSLTR2CYSLTR1
SCHEMBL25244179 0.72 PNP (0.38) KDM4EMAPTKMT2ANPC1RAB9A
SCHEMBL3253637 0.72 CYSLTR1 (0.55) CYSLTR2CYSLTR1LMNACYP1A2ALDH1A1
SCHEMBL267839 0.71 CYSLTR1 (0.53) PDE10ACYSLTR2CYSLTR1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138356-B2 Chemical inhibitors of inhibitors of differentiation Angiogeney, Inc. (US) 2012-03-20 US disclosed
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation ANGIOGENEX 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation BRAF, MAPK1, RAF1 PDE10A 2419/4885KDM4E 1876/4885MAPT 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.